Affordable Access

Publisher Website

Differential regulation of Kidins220 isoforms in Huntington's disease.

  • Sebastián-Serrano, Álvaro1, 2
  • Simón-García, Ana1, 2
  • Belmonte-Alfaro, Alicia1, 2
  • Pose-Utrilla, Julia1, 2
  • Santos-Galindo, María2, 3
  • Del Puerto, Ana1, 2
  • García-Guerra, Lucía1, 2
  • Hernández, Ivó H2, 3, 4
  • Schiavo, Giampietro5
  • Campanero, Miguel R1, 6
  • Lucas, José J2, 3
  • Iglesias, Teresa1, 2
  • 1 Instituto de Investigaciones Biomédicas "Alberto Sols", Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain. , (Spain)
  • 2 Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain. , (Spain)
  • 3 Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Madrid, Spain. , (Spain)
  • 4 Facultad de Ciencias, Departamento de Biología (Unidad Docente Fisiología Animal), Universidad Autónoma de Madrid, Madrid, Spain. , (Spain)
  • 5 Department of Neuromuscular Disorders, UCL Institute of Neurology, University College London, London, UK.
  • 6 Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. , (Spain)
Published Article
Brain Pathology
Wiley (Blackwell Publishing)
Publication Date
Jan 01, 2020
DOI: 10.1111/bpa.12761
PMID: 31264746


Huntington's disease (HD) is an inherited progressive neurodegenerative disease characterized by brain atrophy particularly in the striatum that produces motor impairment, and cognitive and psychiatric disturbances. Multiple pathogenic mechanisms have been proposed including dysfunctions in neurotrophic support and calpain-overactivation, among others. Kinase D-interacting substrate of 220 kDa (Kidins220), also known as ankyrin repeat-rich membrane spanning (ARMS), is an essential mediator of neurotrophin signaling. In adult brain, Kidins220 presents two main isoforms that differ in their carboxy-terminal length and critical protein-protein interaction domains. These variants are generated through alternative terminal exon splicing of the conventional exon 32 (Kidins220-C32) and the recently identified exon 33 (Kidins220-C33). The lack of domains encoded by exon 32 involved in key neuronal functions, including those controlling neurotrophin pathways, pointed to Kidins220-C33 as a form detrimental for neurons. However, the functional role of Kidins220-C33 in neurodegeneration or other pathologies, including HD, has not been explored. In the present work, we discover an unexpected selective downregulation of Kidins220-C33, in the striatum of HD patients, as well as in the R6/1 HD mouse model starting at early symptomatic stages. These changes are C33-specific as Kidins220-C32 variant remains unchanged. We also find the early decrease in Kidins220-C33 levels takes place in neurons, suggesting an unanticipated neuroprotective role for this isoform. Finally, using ex vivo assays and primary neurons, we demonstrate that Kidins220-C33 is downregulated by mechanisms that depend on the activation of the protease calpain. Altogether, these results strongly suggest that calpain-mediated Kidins220-C33 proteolysis modulates onset and/or progression of HD. © 2019 International Society of Neuropathology.

Report this publication


Seen <100 times